These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38336348)

  • 1. Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels.
    Qi R; Fu R; Lei X; He J; Jiang Y; Zhang L; Wu Y; Wang S; Guo X; Chen F; Nie M; Yang M; Chen Y; Zeng J; Xu J; Xiong H; Fang M; Que Y; Yao Y; Wang Y; Cao J; Ye H; Zhang Y; Zheng Z; Cheng T; Zhang J; Lin X; Yuan Q; Zhang T; Xia N
    J Hepatol; 2024 May; 80(5):714-729. PubMed ID: 38336348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
    Su J; Brunner L; Ates Oz E; Sacherl J; Frank G; Kerth HA; Thiele F; Wiegand M; Mogler C; Aguilar JC; Knolle PA; Collin N; Kosinska AD; Protzer U
    J Hepatol; 2023 Apr; 78(4):717-730. PubMed ID: 36634821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
    Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
    J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.
    Zhang TY; Guo XR; Wu YT; Kang XZ; Zheng QB; Qi RY; Chen BB; Lan Y; Wei M; Wang SJ; Xiong HL; Cao JL; Zhang BH; Qiao XY; Huang XF; Wang YB; Fang MJ; Zhang YL; Cheng T; Chen YX; Zhao QJ; Li SW; Ge SX; Chen PJ; Zhang J; Yuan Q; Xia NS
    Gut; 2020 Feb; 69(2):343-354. PubMed ID: 30926653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Booster immunization improves the generation of T follicular helper (Tfh) cells specific to hepatitis B surface antigen (HBsAg) after prenatal HBsAg exposure.
    Wang R; Chen K; Wang Y; Liu C; Wu Z; Wang D; Qu C
    Vaccine; 2021 Sep; 39(39):5571-5579. PubMed ID: 34412920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer.
    Akbar SM; Furukawa S; Hasebe A; Horiike N; Michitaka K; Onji M
    Int J Mol Med; 2004 Aug; 14(2):295-9. PubMed ID: 15254781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers.
    Zhang Y; Bourgine M; Wan Y; Song J; Li Z; Yu Y; Jiang W; Zhou M; Guo C; Santucci D; Liang X; Brechot C; Zhang W; Charneau P; Wu H; Qiu C
    J Hepatol; 2024 Jan; 80(1):31-40. PubMed ID: 37827470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice.
    Michler T; Kosinska AD; Festag J; Bunse T; Su J; Ringelhan M; Imhof H; Grimm D; Steiger K; Mogler C; Heikenwalder M; Michel ML; Guzman CA; Milstein S; Sepp-Lorenzino L; Knolle P; Protzer U
    Gastroenterology; 2020 May; 158(6):1762-1775.e9. PubMed ID: 32001321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine.
    Krawczyk A; Ludwig C; Jochum C; Fiedler M; Heinemann FM; Shouval D; Roggendorf M; Roggendorf H; Lindemann M
    Vaccine; 2014 Sep; 32(39):5077-82. PubMed ID: 24975813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice.
    Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z
    Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-mediated immunotherapy against chronic hepatitis B virus infection.
    Gao Y; Zhang TY; Yuan Q; Xia NS
    Hum Vaccin Immunother; 2017 Aug; 13(8):1768-1773. PubMed ID: 28521640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen.
    Zhang TY; Yuan Q; Zhao JH; Zhang YL; Yuan LZ; Lan Y; Lo YC; Sun CP; Wu CR; Zhang JF; Zhang Y; Cao JL; Guo XR; Liu X; Mo XB; Luo WX; Cheng T; Chen YX; Tao MH; Shih JW; Zhao QJ; Zhang J; Chen PJ; Yuan YA; Xia NS
    Gut; 2016 Apr; 65(4):658-71. PubMed ID: 26423112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.
    Böcher WO; Herzog-Hauff S; Schlaak J; Meyer zum Büschenfeld KH; Löhr HF
    Hepatology; 1999 Jan; 29(1):238-44. PubMed ID: 9862872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds.
    Tsebe KV; Burnett RJ; Hlungwani NP; Sibara MM; Venter PA; Mphahlele MJ
    Vaccine; 2001 Jul; 19(28-29):3919-26. PubMed ID: 11427266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal route favors the induction of CD4
    Bourgine M; Crabe S; Lobaina Y; Guillen G; Aguilar JC; Michel ML
    Antiviral Res; 2018 May; 153():23-32. PubMed ID: 29510155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus vaccination booster does not provide additional protection in adolescents: a cross-sectional school-based study.
    Chang YC; Wang JH; Chen YS; Lin JS; Cheng CF; Chu CH
    BMC Public Health; 2014 Sep; 14():991. PubMed ID: 25248369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.
    Wang X; Dong A; Xiao J; Zhou X; Mi H; Xu H; Zhang J; Wang B
    Cell Mol Immunol; 2016 Nov; 13(6):850-861. PubMed ID: 26166767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity.
    Werner JM; Abdalla A; Gara N; Ghany MG; Rehermann B
    Gastroenterology; 2013 Nov; 145(5):1026-34. PubMed ID: 23916846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.